The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Hims and Hers (HIMS). Peptides Are Starting to Sound. : r AsymmetricAlpha Restoring Balance: What the FDA's Peptide Announcement Could Mean for Patient Access and Safety Empower Pharmacy RFK Jr. & claimed regenerative peptides like BPC 157 The Niche Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # HHS Secretary RFK Jr. just dropped major news: the FDA is removing 12 peptides from its restrictive Category 2 list reversing the 2023 crackdown that shut down compounding pharmacies and fueled